Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Stay updated with breaking news from Alan Korman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation".
Workers in the Biond Biologics lab in Misgav, Israel (Courtesy) The anti-cancer drug developed by Biond Biologics, which the Israeli startup will now try on humans in clinical trials with France-based multinational Sanofi, takes a multipronged approach to fighting tumors, activating three kind of cells in the immune system at the same time. Paris-based multinational pharma firm Sanofi signed a licensing agreement earlier this month for Biond’s flagship anti-tumor drug BND-22, a cancer immunotherapy medication. Under the terms of the agreement, Biond will receive an upfront payment of $125 m...